Communiqués Compugen Ltd. TEL AVIV STOCK EXCHANGE

Actions

CGEN

IL0010852080

Recherche biotechnologique et médicale

Marché Fermé - TEL AVIV STOCK EXCHANGE Autres places de cotation 12:44:58 07/08/2026			Varia. 5j.	Varia. 1 janv.
684,20 ^ILa	-1,13%		-3,32%	+46,20%

03/08	Compugen Ltd. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
03/08	Transcript : Compugen Ltd., Q2 2026 Earnings Call, Aug 03, 2026

Communiqués

03/08	Compugen : Corporate Presentation	PU
03/08	Compugen : CGEN Corporate Deck	PU
03/08	Compugen: Q2 Earnings Snapshot	AQ
03/08	Compugen Reports Second Quarter 2026 Results	PR
21/07	Compugen to Participate in BTIG Biotechnology Conference 2026	PR
18/06	Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress	PR
11/06	Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026	PR
08/06	Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development	PR
19/05	Compugen : Corporate Presentation	PU
18/05	Compugen: Q1 Earnings Snapshot	AQ
18/05	Compugen : First Quarter 2026 Press Release	PU
18/05	Compugen Reports First Quarter 2026 Results	PR
12/05	Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum	PR
02/03	Compugen: Q4 Earnings Snapshot	AQ
02/03	Compugen : Corporate Presentation	PU
02/03	Compugen : Fourth Quarter 2025 Press Release	PU
02/03	Compugen Reports Fourth Quarter and Full Year 2025 Results	PR
17/02	Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026	PR
12/02	Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors	PR
17/12	Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million	PR
10/11	Compugen: Q3 Earnings Snapshot	AQ
10/11	Compugen : Reports Third Quarter 2025 Results	PU
04/11	Compugen to Participate in Stifel 2025 Healthcare Conference	PR
27/10/25	Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025	PR
13/10/25	Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025	PR